Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B

Gilteritinib, an FDA-approved tyrosine kinase inhibitor approved for the treatment of relapsed/refractory FLT3-mutated acute myeloid leukemia, is primarily eliminated via CYP3A4-mediated metabolism, a pathway that is sensitive to the co-administration of known CYP3A4 inhibitors, such as itraconazole...

Descripción completa

Detalles Bibliográficos
Autores principales: Garrison, Dominique A., Jin, Yan, Talebi, Zahra, Hu, Shuiying, Sparreboom, Alex, Baker, Sharyn D., Eisenmann, Eric D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610999/
https://www.ncbi.nlm.nih.gov/pubmed/36296409
http://dx.doi.org/10.3390/molecules27206815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610999/
https://www.ncbi.nlm.nih.gov/pubmed/36296409
http://dx.doi.org/10.3390/molecules27206815

Ejemplares similares